Tag: Boehringer

Posted on

Propeller Health and Boehringer Ingelheim Collaborate on COPD, Asthma Tools for Better Health – COPD News Today


Drug Discovery & Development

Propeller Health and Boehringer Ingelheim Collaborate on COPD, Asthma Tools for Better Health
COPD News Today
Boehringer Ingelheim Pharmaceuticals and Propeller Health are partnering to use digital health tools and services to help patients with asthma and chronic obstructive pulmonary disease (COPD) to better cope with their condition. Under the terms of the …
FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim's STIOLTO RESPIMAT for COPD …PR Newswire (press release)
Boehringer Ingelheim Enters Commercial Partnership with Propeller HealthPharmaceutical Technology Magazine (press release) (blog)

all 3 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim’s asthma drug wins FDA approval – Danbury News Times


Danbury News Times

Boehringer Ingelheim's asthma drug wins FDA approval
Danbury News Times
DANBURY — Nearly one in 10 adults in Connecticut – 9.2 percent – has asthma. Boehringer Ingelheim, the Danbury-based pharmaceutical company cited the figure as it announced the federally approved availability of its new Spiriva Respimat product for …
Spiriva Respimat Now Available in Pharmacies for Asthma PatientsPharmacy Times

all 3 news articles »

View full post on asthma – Google News

Posted on

Boehringer Presents New Phase III Data for Asthma Therapy Tiotropium – Lung Disease News

Boehringer Presents New Phase III Data for Asthma Therapy Tiotropium
Lung Disease News
Boehringer Ingelheim Pharmaceutical company Boehringer Ingelheim recently presented encouraging data regarding its investigational drug tiotropium delivered through the company's Respimat inhaler, for the treatment of asthma. The data was presented …
Tiotropium improves lung function in asthma, regardless of allergic statusHealio

all 2 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma … – Drug Discovery & Development

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
Drug Discovery & Development
Boehringer Ingelheim announced new data from large scale, Phase 3 studies showing that once-daily tiotropium delivered via the Respimat inhaler was effective and well tolerated in patients across asthma severities. These data were presented at the …
Tiotropium as Asthma Add-On Treatment Shows PromiseMonthly Prescribing Reference

all 7 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma … – PR Newswire (press release)

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
PR Newswire (press release)
RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ — Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat® inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, …

and more »

View full post on asthma – Google News

Posted on

Phase III Success for Boehringer Ingelheim Asthma Drug – Genetic Engineering News

Phase III Success for Boehringer Ingelheim Asthma Drug
Genetic Engineering News
Boehringer-Ingelheim said today its once-daily asthma drug tiotropium, delivered via Respimat® Soft Mist™ Inhaler, produced favorable Phase III results by increasing the time to first severe exacerbation, and time to first episode of asthma worsening …
Boehringer Ingelheim's tiotropium shows promising results in patients with …News-Medical.net
Phase III results: tiotropium* Respimat® effective in symptomatic asthma …EON: Enhanced Online News (press release)
Boehringer Ingelheim reports positive data from symptomatic asthma trialsZenopa

all 5 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim’s tiotropium shows promising results in patients with … – News-Medical.net

Boehringer Ingelheim's tiotropium shows promising results in patients with …
News-Medical.net
Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society …
Phase III results: tiotropium* Respimat® effective in symptomatic asthma …EON: Enhanced Online News (press release)
Boehringer Ingelheim reports positive data from symptomatic asthma trialsZenopa

all 3 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma … – The Pharma Letter

Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma …
The Pharma Letter
German family-owned drug major Boehringer Ingelheim presented a new subset of data from the Phase III UniTinA-asthma program relating to its already-marketed drug Spiriva (tiotropium) at the 2013 American Academy of Allergy, Asthma & Immunology …
Boehringer Ingelheim drug shows benefits in new asthma trialZenopa

all 2 news articles »

View full post on asthma – Google News